This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.





Hepatocellular carcinoma is an increasing threat in most countries in the world. Although there are programs that allow early detection and curative treatment most cancers are still only diagnosed late. At this late stage treatment of the cancer is complicated by the presence of liver disease, which may be advanced, and which may alter the pharmacokinetics of any drug used to treat the cancer.

Thus there are many gaps in our approach to managing this disease. We need to better understand the epidemiology, in particular why so few patients are diagnosed early. Although our knowledge of the biology of this cancer has improved by leaps and bounds in the recent past we still do not understand the pathogenesis fully, and we are unable to target metabolic pathways that might effectively treat the cancer. There has been progress in chemotherapy of advanced disease, but we are still a long way from the possibility of cure of intermediate or late stage disease.

This series of presentations at the Global Hepatitis Summit will bring together experts in several different areas of research on hepatocellular carcinoma to discuss the state of the art in their areas to highlight where we are and where we need to go in future.



Date: Friday, June 15, 2018
Time: 10:30 - 18:00
Included: in Day Pass for June 15, or Full Summit Pass

Symposium Program

Session 1 -  General Session (10:30-12:10)

1. Global epidemiology of HCC in the 21st Century:  Changing etiology of liver disease

a. Brian McMahon

2. Pathogenesis of HCC: Genetic and epigenetic factors

a. Thomas Baumert

3. HCC surveillance:  How, When and What to do with a positive result

a. Morris Sherman

4. Strategies to improve Healthcare delivery for HCC:  A Multidisciplinary approach

a. David Kaplan


Session 2 -  Hepatitis B and HCC (14:00-15:40)

1. Oncogenesis of HBV-related HCC – virus vs. inflammation

a. Massimo Levrero

2. Epidemiology of HBV-related HCC – continental perspectives

a. Lewis Roberts

3. Assessing HCC risk in Hepatitis B:  How to use different scoring systems

a. George Papatheordorides

4. Development of HCC in patients with suppressed viral replication: Changes in risk over time

a. Ray Kim


Session 3 -  Hepatitis C and HCC (16:15-18:00)

1. Assessing HCC risk:  who should undergo surveillance (this would include post SVR)

a. Norah Terrault

2. Does the presence of HCC alter the response to HCV treatment

a. Greg Dore

3. Recurrence of HCC after Therapy for HCV:  Fact or Fiction.  

a. Antonio Craxi

4. Liver transplantation for HCC in hepatitis C:  What are the issues

a. Xavier Forns


Supported by AASLD. The GHA is pleased to have received the support of the American Association for the Study of Liver Diseases for the AASLD-EASL-ISVHLD Joint Symposium and the AASLD-ALEH-CASL Pan-American Session.



The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.